These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36302966)

  • 1. Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder.
    Ho MF; Zhang C; Moon I; Zhu X; Coombes BJ; Biernacka J; Skime M; Oesterle TS; Karpyak VM; Schmidt K; Gliske K; Ngo Q; Skillon C; Seppala MD; Li H; Weinshilboum RM
    Mol Psychiatry; 2024 Jun; 29(6):1636-1646. PubMed ID: 36302966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.
    Han B; Jones CM; Einstein EB; Compton WM
    JAMA Netw Open; 2021 Oct; 4(10):e2129409. PubMed ID: 34652446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report.
    Patel KV; Sahni S; Taylor LF
    J Osteopath Med; 2023 Jan; 123(1):1-5. PubMed ID: 36282967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder.
    Varisco T; Shen C; Thornton D
    J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
    Kuo A; Wyse BD; Meutermans W; Smith MT
    Br J Pharmacol; 2015 Jan; 172(2):532-48. PubMed ID: 24641546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.
    De Aquino JP; Parida S; Avila-Quintero VJ; Flores J; Compton P; Hickey T; Gómez O; Sofuoglu M
    Drug Alcohol Depend; 2021 Nov; 228():109097. PubMed ID: 34601272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive.
    Webster LR; Hansen E; Cater J; Smith T
    Adv Ther; 2020 Nov; 37(11):4685-4696. PubMed ID: 32978722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.
    Bossert JM; Kiyatkin EA; Korah H; Hoots JK; Afzal A; Perekopskiy D; Thomas S; Fredriksson I; Blough BE; Negus SS; Epstein DH; Shaham Y
    Biol Psychiatry; 2020 Dec; 88(12):935-944. PubMed ID: 32305216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.